title: Effect of Intravenous Administration of Liposomal Prostaglandin E1 on Microcirculation in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.
abstract: BACKGROUND
  Several studies have demonstrated that primary percutaneous coronary intervention (PCI) can result in reperfusion injury. This study aims to investigate the effectiveness of liposomal prostaglandin E1 (Lipo-PGE1, Alprostadil, Beijing Tide Pharmaceutical Co., Ltd.) for enhancing microcirculation in reperfusion injury. In addition, this study determined the optimal administration method for acute ST elevation myocardial infarction (STEMI) patients undergoing primary PCI.
  
  
  METHODS
  Totally, 68 patients with STEMI were randomly assigned to two groups: intravenous administration of Lipo-PGE1 (Group A), and no Lipo-PGE1 administration (Group B). The corrected thrombolysis in myocardial infarction (TIMI) frame count (cTFC) and myocardial blush grade (MBG) were calculated. Patients were followed up for 6 months. Major adverse cardiac events (MACE) were also measured.
  
  
  RESULTS
  There was no significant difference in the baseline characteristics between the two groups. The cTFC parameter in Group A was significantly lower than Group B (18.06 ± 2.06 vs. 25.31 ± 2.59, P < 0.01). The ratio of final MBG grade-3 was significantly higher (P < 0.05) in Group A (87.9%) relative to Group B (65.7%). There was no significant difference between the two groups in final TIMI-3 flow and no-reflow. Patients were followed up for 6 months, and the occurrence of MACE in Group A was significantly lower than that in Group B (6.1% vs. 25.9% respectively, P < 0.05).
  
  
  CONCLUSIONS
  Myocardial microcirculation of reperfusion injury in patients with STEMI, after primary PCI, can be improved by administering Lipo-PGE1.
authors.forename: Li-Ye
authors.initials: LY
authors.lastname: Wei
authors.affiliation: Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
authors.forename: Xiang-Hua
authors.initials: XH
authors.lastname: Fu
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Xi-Le
authors.initials: XL
authors.lastname: Bi
authors.forename: Shi-Ru
authors.initials: SR
authors.lastname: Bai
authors.forename: Kun
authors.initials: K
authors.lastname: Xing
authors.forename: Yan-Bo
authors.initials: YB
authors.lastname: Wang
mesh_terms: D061605:Administration, Intravenous; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D062645:Percutaneous Coronary Intervention / Q000379:methods*
chemical_list: D000527:Alprostadil